Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Carl-Åke Carlsson
|
| gptkbp:foundedYear |
1903
|
| gptkbp:headquartersLocation |
gptkb:Copenhagen,_Denmark
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xellia Pharmaceuticals
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:manufacturingFacilities |
gptkb:Budapest,_Hungary
gptkb:Copenhagen,_Denmark gptkb:Zagreb,_Croatia gptkb:Bedford,_Ohio,_USA |
| gptkbp:operatesIn |
global
|
| gptkbp:parentCompany |
gptkb:Novo_Holdings
|
| gptkbp:products |
gptkb:daptomycin
gentamicin vancomycin colistimethate sodium |
| gptkbp:specializesIn |
injectable antibiotics
anti-infective treatments |
| gptkbp:website |
https://www.xellia.com/
|
| gptkbp:bfsParent |
gptkb:Novo_Holdings
|
| gptkbp:bfsLayer |
7
|